Glioma pathophysiology: Insights emerging from proteomics

Brain Pathology

Volumn 20, Issue 4, 2010, Pages 691-703

  Deighton, Ruth F ^a,b   McGregor, Richard ^a,b   Kemp, Jocelyn ^a,b   McCulloch, James ^a,b   Whittle, Ian R ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Functional networks; Glioblastoma; Glioma pathophysiology; Proteomics

Indexed keywords

APOLIPOPROTEIN A1; BONE MORPHOGENETIC PROTEIN 15; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 70; PROHIBITIN; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE ASSOCIATED 3; PROTEIN P53; PROTEIN RHO GD1; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; RHO FACTOR; SERUM ALBUMIN; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; CANCER GRADING; CARCINOGENESIS; CLINICAL RESEARCH; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION; GENOMICS; GLIOBLASTOMA; GLIOMA; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEOMICS; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMATIC REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; WESTERN BLOTTING; BRAIN TUMOR; METABOLISM; PATHOLOGY;

BRAIN NEOPLASMS; GLIOMA; HUMANS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953222551     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2010.00376.x     Document Type: Review

References (90)

1. Albrethsen J, Knol JC, Jimenez CR (2009) Unravelling the nuclear matrix proteome. J Proteome 72 : 71 81.
2. Anderson E, Grant R, Lewis SC, Whittle IR (2008) Randomized phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg 22 : 339 349.
3. Asamoto M, Cohen SM (1994) Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines. Cancer Lett 83 : 201 207. (Pubitemid 24253539)
4. Banks R, Selsby P (2003) Clinical proteomics - insights into pathologies and benefits for patients. Lancet 362 : 415 416.
5. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A et al (2001) Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7 : 2387 2395.
6. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20 : 1063 1068.
7. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A et al (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22 : 1926 1933.
8. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC et al (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93 : 8502 8507.
9. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Campbell CM et al (2005) Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 115 : 1239 1242.
10. Chumbalkar V, Sawaya R, Bogler O (2008) Proteomics: the new frontier also for brain tumor research. Curr Probl Cancer 32 : 143 154.
11. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN et al (2005) Differential protein expression in human gliomas and molecular insights. Proteomics 5 : 1167 1177.
12. Collins VP (1998) Gliomas. Cancer Surv 32 : 37 51.
13. Deighton RF, Short DM, McGregor RJ, Gow AJ, Whittle IR, McCulloch J (2009) The utility of functional interaction and cluster analysis in CNS proteomics. J Neurosci Methods 180 : 321 329.
14. Djebbari A, Quackenbush J (2008) Seeded Bayesian Networks: constructing genetic networks from microarray data. BMC Syst Biol 2 : 57.
15. Duffy PE, Graf L, Rapport MM (1977) Identification of glial fibrillary acidic protein by the immunoperoxidase method in human brain tumors. J Neuropathol Exp Neurol 36 : 645 652.
16. Fasa VM, Hanash SM (2009) In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res 69 : 728 730.
17. Frazoni A, Dima M, D'Agnostino M, Puppin C, Fabbro D, Loreto CD et al (2009) Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF (V600E) mutation. Thyroid 19 : 247 255.
18. Frezza C, Gottlieb E (2009) Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 19 : 4 11.
19. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN et al (2004) Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23 : 6806 6814.
20. Fuxius S, Eravci M, Broedel O, Weist S, Mansmann U, Eravci S et al (2008) Technical strategies to reduce the amount of "false significant" results in quantitative proteomics. Proteomics 8 : 1780 1784.
21. Gammeltoft S, Ballotti R, Kowalski A, Westermark B, Van Obberghen E (1988) Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res 48 : 1233 1237.
22. Grandemange S, Herzig S, Martinou JC (2009) Mitochondrial dynamics and cancer. Semin Cancer Biol 19 : 50 56.
23. Grant SG (2006) The synapse proteome and phosphoproteome: a new paradigm for synapse biology. Biochem Soc Trans 34 : 59 63.
24. Griffith OL, Chiu CG, Gown AM, Jones SJ, Wiseman SM (2008) Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther 8 : 1399 1413.
25. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997 1003.
26. Helseth E, Dalen A, Unsgaard G, Vik R (1988) Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line. J Neurooncol 6 : 277 283. (Pubitemid 19022026)
27. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T (1993) Expression of tenascin in human gliomas: its relation to histological malignancy,tumor dedifferentiation and angiogenesis. Acta Neuropathol 85 : 481 487.
28. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H et al (2003) Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 309 : 558 566.
29. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD (2003) Magnetic Resonance Image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 18 : 530 536.
30. Holcakova J, Hernychova L, Bouchal P, Brozkova K, Zaloudik J, Valik D et al (2008) Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS. Int J Biol Markers 23 : 48 53.
31. Holtkamp N, Afanasieva A, Elstner A, van Landeghen FK, Konneker M, Kuhn SA et al (2005) Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochem Biophys Res Commun 336 : 1227 1233.
32. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, El-Yazidi-Belkoura I, Nurcombe V et al (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1 : 1216 1232.
33. Hondermarck H, Tastet C, El Yazidi-Belkoura I, Toillon RA, Le Bourhis X (2008) Proteomics of breast cancer: the quest for markers and therapeutic targets. J Proteome Res 7 : 1403 1411.
34. Huse JT, Holland EC (2009) Genetically engineered mouse models of brain cancer and the promise ofpreclinical testing. Brain Pathol 19 : 132 143.
35. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M et al (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64 : 2496 2501.
36. Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I et al (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6 : 2964 2971.
37. Jimenez CR (2009) Sorting and Zooming: subcellular proteomics is booming. J Proteomics 72 : 1 3.
38. Khalil AA (2007) Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 98 : 201 213.
39. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J et al (1997) Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150 : 805 814.
40. Kruse U, Bantscheff M, Drewes G, Hopf C (2008) Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalised health care. Mol Cell Proteomics 7 : 1887 1901.
41. Latterich M, Abramovitz M, Leyland-Jones B (2008) Proteomics: new technologies and clinical applications. Eur J Cancer 44 : 2737 2741.
42. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 : 144 147.
43. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57 : 5254 5257.
44. Malinowski DP (2007) Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn 7 : 117 131.
45. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 : 2012 2024.
46. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A et al (2007) Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 1 : 148 156.
47. Mishra S, Murphy LC, Nyomba BLG, Murphy LJ (2005) Prohibitin: a potential target for new therapeutics. Trends Mol Med 11 : 192 197.
48. Mishra S, Murphy LC, Murphy LJ (2006) The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 10 : 353 363.
49. Morandell S, Stasyk T, Grosstessner-Haink K, Roitinger E, Mechtler K, Bonn GK et al (2006) Phosphoproteomic stategies for the functional analysis of signal transduction. Proteomics 6 : 4047 4056.
50. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA (2008) Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signalling network. Proteomics 8 : 4383 4401.
51. Moriyama T, Kataoka H, Tsubouchi H, Koono M (1995) Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro. FEBS Lett 372 : 78 82.
52. Mustafa DAN, Burgers PC, Dekker LJ, Charif H, Titulaer MK, Sillevis Smitt PAE et al (2007) Identification of glioma neovascularization-related proteins by using MALDI-FTMS and Nano-LC fractionation to microdissected tumor vessels. Mol Cell Proteomics 6-7 : 1147 1157.
53. Nistér M, Heldin CH, Wasteson A, Westermark B (1984) A glioma-derived analog to platelet-derived growth factor: demonstration of receptor competing activity and immunological crossreactivity. Proc Natl Acad Sci USA 81 : 926 930.
54. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B et al (2005) Proteomic studies on low- and high- grade human brain astrocytomas. J Proteome Res 4 : 698 708.
55. Ou K, Yu K, Kesuma D, Hooi M, Huang N, Chen W et al (2008) Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res 7 : 1518 1528.
56. Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, Garrido C (2005) Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal 7 : 404 413.
57. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807 1812.
58. Petrak J, Ivanek R, Toman O, Cmejla R et al (2008) Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8 : 1744 1749.
59. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4 : 568 580.
60. Rajalingham K, Rudel T (2005) Ras-Raf signalling needs prohibitin. Cell Cycle 4 : 1503 1505.
61. Rajalingham K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C et al (2005) Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nature Cell Biology 7 : 837 843.
62. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53 : 2736 2739.
63. Reymond MA, Schlegel W (2007) Proteomics in cancer. Adv Clin Chem 44 : 103 142.
64. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA (2002) Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry 72 : 262 265.
65. Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16 : 607 613.
66. Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME (2008) Differences in mitochondrial function and anti-oxidant systams between regions of human glioma. Cell Physiol Biochem 22 : 757 768.
67. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM (2004) Protein profiling in brain tumours using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 10 : 981 987.
68. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65 : 7674 7681.
69. Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol (Berl) 73 : 145 152.
70. Service RF (2008) NewsFocus: proteomics ponders prime time. Science 321 : 1758 1761.
71. Short DM, Heron ID, Birse-Archbold JLA, Kerr LE, Sharkey J, McCulloch J (2007) Apoptosis induced by staurosporine alters chaperone and endoplasmic reticulum proteins: identification by quantitative proteomics. Proteomics 7 : 3085 3096.
72. Soni D, King JAJ, Kaye AH, Hovens CM (2005) Genetics of glioblastoma multiforme: mitogenic signalling and cell cycle converge. J Clin Neurosci 12 : 1 5.
73. Sowell RA, Owen JB, Butterfield DA (2009) Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 8 : 1 17.
74. Sun S, Lee NP, Poon RT, Fan ST, He QY, Lau GK, Luk JM (2007) Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int 27 : 1021 1038.
75. Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM (2009) Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med 1 : 57.
76. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterisation defines human glioblastoma genes and core pathways. Nature 455 : 1061 1068.
77. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J et al (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266 : 171 185.
78. Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B et al (2008) Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer 98 : 1830 1838.
79. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57 : 4183 4186.
80. Wharton SB, McNelis U, Bell HS, Whittle IR (2000) Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol 26 : 528 535.
81. Whittle IR (1992) The origins and management of peritumoural brain dysfunction. Neurosurg Quart 2 : 173 198.
82. Whittle IR, Short DM, Deighton RF, Kerr LE, Smith C, McCulloch J (2007) Proteomic analysis of glioma. Br J Neurosurg 21 : 576 582.
83. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57 : 4130 4140.
84. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC et al (2009) Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 6 : 123 134.
85. Wrensch M, Jenkins RB, Chang JS, Yeh R-F, Xiao Y, Decker PA et al (2009) Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nature Genet 41 : 905 908.
86. Yu W, Sanders BG, Kline K (2003) RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cells involves Bax translocation to mitochondria. Cancer Res 63 : 2483 2491.
87. Yurkovestky ZR, Linkov FY, E Malehon D, Lokshin AE (2006) Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2 : 733 741.
88. Zanivan S, Gnad F, Wickstrom SA, Geiger T, Macek B, Cox J et al (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7 : 5314 5326.
89. Zhang J, Keene CD, Pan C, Montine KS, Montine TJ (2008) Proteomics of human neurodegenerative diseases. J Neuropathol Exp Neurol 67 : 923 932.
90. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455 : 1129 1133.